ES2328474T3 - Preparacion de iscom y su utilizacion. - Google Patents

Preparacion de iscom y su utilizacion. Download PDF

Info

Publication number
ES2328474T3
ES2328474T3 ES03738849T ES03738849T ES2328474T3 ES 2328474 T3 ES2328474 T3 ES 2328474T3 ES 03738849 T ES03738849 T ES 03738849T ES 03738849 T ES03738849 T ES 03738849T ES 2328474 T3 ES2328474 T3 ES 2328474T3
Authority
ES
Spain
Prior art keywords
iscom
complexes
complex
mixture
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03738849T
Other languages
English (en)
Inventor
Bror Morein
Bengtsson Karin Lovgren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Isconova AB
Original Assignee
Isconova AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isconova AB filed Critical Isconova AB
Application granted granted Critical
Publication of ES2328474T3 publication Critical patent/ES2328474T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Composición que comprende por lo menos dos complejos iscom diferentes, comprendiendo cada uno de los complejos diferentes una fracción de saponina de Quillaja Saponaria Molina, en la que la fracción de saponina en un complejo es diferente de la fracción de saponina en el otro complejo, presentando actividad inmunomoduladora, actividad adyuvante amplificada y toxicidad reducida.
ES03738849T 2002-07-05 2003-07-07 Preparacion de iscom y su utilizacion. Expired - Lifetime ES2328474T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202110A SE0202110D0 (sv) 2002-07-05 2002-07-05 Iscom preparation and use thereof

Publications (1)

Publication Number Publication Date
ES2328474T3 true ES2328474T3 (es) 2009-11-13

Family

ID=20288449

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03738849T Expired - Lifetime ES2328474T3 (es) 2002-07-05 2003-07-07 Preparacion de iscom y su utilizacion.

Country Status (14)

Country Link
US (3) US20060121065A1 (es)
EP (1) EP1539231B1 (es)
JP (1) JP4636877B2 (es)
AT (1) ATE434443T1 (es)
AU (1) AU2003245220B2 (es)
BR (1) BRPI0312472B8 (es)
CA (1) CA2491457C (es)
DE (1) DE60328108D1 (es)
DK (1) DK1539231T3 (es)
ES (1) ES2328474T3 (es)
NZ (1) NZ537661A (es)
SE (1) SE0202110D0 (es)
WO (1) WO2004004762A1 (es)
ZA (1) ZA200500073B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
DK1838341T3 (da) 2005-01-20 2013-11-04 Isconova Ab Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
EP1764369A1 (de) * 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
WO2008031878A1 (en) * 2006-09-15 2008-03-20 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
EP1902727A1 (de) * 2006-09-22 2008-03-26 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN103052401A (zh) 2010-07-23 2013-04-17 伊斯克诺瓦公司 流感疫苗
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
AU2012319239B2 (en) 2011-10-03 2017-04-20 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
MY170927A (en) 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
MY169352A (en) 2012-03-22 2019-03-25 Janssen Vaccines & Prevention Bv Vaccine against rsv
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2014135651A1 (en) 2013-03-08 2014-09-12 Crucell Holland B.V. Acellular pertussis vaccine
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
SG11201509663PA (en) 2013-05-30 2015-12-30 Crucell Holland Bv Influenza virus vaccines and uses thereof
BR112015031509B1 (pt) 2013-06-17 2023-05-09 Janssen Vaccines & Prevention B.V. Polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) pré- fusão recombinante e composição que o compreende
EP3017040B1 (en) 2013-07-02 2018-06-06 Janssen Vaccines & Prevention B.V. Method for preparing virosomes
US10806779B2 (en) 2013-07-02 2020-10-20 Janssen Vaccines & Prevention B.V. Method for preparing virosomes
KR101821712B1 (ko) 2013-08-22 2018-01-24 주식회사 아데나 삼칠근 추출물, 비누풀잎 추출물, 검정콩 잎 추출물, 녹두 잎 추출물 및 호랑이콩 잎 추출물을 포함하는 Ｔｈ2-매개 면역 질환 개선, 예방 또는 치료용 조성물
EP3587442A1 (en) 2014-07-10 2020-01-01 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
PT3215187T (pt) 2014-11-04 2018-11-27 Janssen Vaccines & Prevention Bv Vacinas terapêuticas contra hpv16
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
CA2991540A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides
MX2018002106A (es) 2015-08-20 2018-06-15 Janssen Vaccines & Prevention Bv Vacunas terapeuticas contra el hpv18.
EP3344288A1 (en) 2015-09-02 2018-07-11 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
MX2018002728A (es) 2015-09-03 2018-09-05 Novavax Inc Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
KR102136678B1 (ko) 2015-12-23 2020-07-22 화이자 인코포레이티드 Rsv f 단백질 돌연변이체
MX2018012095A (es) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Vacuna contra vrs.
WO2017174568A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins
JP7053491B2 (ja) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用ｈｐｖワクチン組み合わせ
US11473105B2 (en) 2016-05-12 2022-10-18 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
MX2018015540A (es) 2016-06-20 2019-04-11 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
CA3073790A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
PT3743106T (pt) 2018-01-23 2022-08-24 Janssen Vaccines & Prevention Bv Vacinas contra o vírus da influenza e suas utilizações
CA3092984A1 (en) 2018-03-19 2019-09-26 Novavax, Inc. Multivalent influenza nanoparticle vaccines
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
JP2021524449A (ja) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム 分子アジュバント
CN113164583A (zh) 2018-11-13 2021-07-23 扬森疫苗与预防公司 稳定的融合前rsv f蛋白
JP2022530439A (ja) 2019-04-25 2022-06-29 ヤンセン ファッシンズ アンド プリベンション ベーフェー 組換えインフルエンザ抗原
BR112021022087A2 (pt) 2019-05-15 2021-12-28 Janssen Vaccines & Prevention Bv Coadministração de vacina sazonal contra influenza e vacina contra vírus respiratório sincicial à base de adenovírus
CA3140234A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
US20230250135A1 (en) 2019-09-05 2023-08-10 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CN116096732A (zh) 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
CN116096409A (zh) 2020-05-11 2023-05-09 杨森制药公司 编码稳定化的冠状病毒刺突蛋白的rna复制子
AU2021272741A1 (en) 2020-05-11 2023-02-02 Janssen Pharmaceuticals, Inc. SARS-CoV-2 vaccines
CA3183086A1 (en) 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
US20230233661A1 (en) 2020-06-29 2023-07-27 Janssen Vaccines & Prevention B.V. Vaccine combination against repiratory syncytial virus infection
CA3187149A1 (en) 2020-07-06 2022-01-13 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
AU2022221983A1 (en) 2021-02-19 2023-08-17 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
AU2022249741A1 (en) 2021-04-01 2023-09-21 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2023217988A1 (en) 2022-05-12 2023-11-16 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024017682A1 (en) 2022-07-18 2024-01-25 Janssen Vaccines & Prevention B.V. Rsv immunogens
WO2024030856A2 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof

Also Published As

Publication number Publication date
DE60328108D1 (de) 2009-08-06
CA2491457C (en) 2012-09-04
SE0202110D0 (sv) 2002-07-05
US20150209425A1 (en) 2015-07-30
EP1539231B1 (en) 2009-06-24
US20200215189A1 (en) 2020-07-09
AU2003245220A1 (en) 2004-01-23
BRPI0312472B8 (pt) 2021-05-25
ATE434443T1 (de) 2009-07-15
NZ537661A (en) 2008-08-29
JP2006511451A (ja) 2006-04-06
US10729764B2 (en) 2020-08-04
BR0312472A (pt) 2005-04-26
EP1539231A1 (en) 2005-06-15
DK1539231T3 (da) 2009-09-14
CA2491457A1 (en) 2004-01-15
BRPI0312472B1 (pt) 2019-07-16
AU2003245220B2 (en) 2009-04-23
US20060121065A1 (en) 2006-06-08
ZA200500073B (en) 2006-02-22
JP4636877B2 (ja) 2011-02-23
WO2004004762A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
ES2328474T3 (es) Preparacion de iscom y su utilizacion.
NZ512011A (en) Improved saponin adjuvant compositions and methods relating thereto
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
MY129263A (en) Vaccine composition
DK0548114T5 (da) Mometason-furoat-monohydrat, fremgangsmåde til fremtilling deraf og farmaceutiske præparater indeholdende dette
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
WO2006113909A3 (en) Humanized anti-cd70 binding agents and uses thereof
NO20074392L (no) Vaksine
NO20082472L (no) Vaksinesammensetninger omfattende en saponin adjuvant
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
MXPA04001224A (es) Agentes para incrementar la respuesta inmune.
BRPI0609765A8 (pt) mistura de isoalcano, método para a preparação da mesma, composição cosmética ou farmacêutica, e, uso de uma mistura de isoalcano
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
ATE389397T1 (de) Adjuvante zusammensetzungen
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
WO2007031334A3 (en) Vaccines comprising truncated hbc core protein plus saponin-based adjuvants
WO2023235660A3 (en) Flavivirus immunogens and vaccine compositions and methods of using the same
WO2004098529A3 (en) Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
WO2022249106A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR0207447A (pt) Polipeptìdeos e fragmentos de dna correspondentes de streptococcus pyogenes úteis como componentes de vacina
WO2005077412A3 (en) Compositions and methods of use of w-peptides